TCTMD - tctmd.com
WEBEpisode 19: Transcatheter Tricuspid Valve Replacement - Insights from TCT 2023 Part 2. Join us for a discussion on the new data from TCT 2023 on transcatheter tricuspid valve replacement with the Columbia Structural Heart and Valve team. In this episode, delve into not only the latest findings but also the intriguing questions that arise from ...
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
Complications After TAVR: Manageable, But Important to Consider
WEBNov 10, 2011 · Vascular complications after TAVR, including hematomas, dissections and perforations, are frequent and have been associated with increased mortality. Vessel-sheath size ratio, calcification and center experience appear to be important predictors. Meticulous CTA screening, site/operator experience, reduced …
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis
WEBFeb 10, 2020 · To TCTMD, Byrne pointed out that 10-year data from ISAR-TEST 4 and ISAR-TEST 5 have also shown the accrual of stent-related events over time. Even between 5 and 10 years, stent-related adverse events occurred at roughly 1% to 1.5% per year, he said. Long-term data from the SPIRIT trials also showed similar results.
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement ...
WEBOct 26, 2023 · Susheel Kodali. Neil Fam, MD (University of Toronto/St. Michael’s Hospital, Canada), who performed the first-in-human transcatheter tricuspid valve replacement with Evoque (Edwards Lifesciences) more than 4 years ago, called TRISCEND II a “big step forward.”. Even back then, early outcomes looked good, but they’ve since gotten better.
DCB Match DES for Treating Coronary In-Stent Restenosis: …
WEBSep 15, 2021 · By Caitlin E. Cox. For coronary in-stent restenosis (ISR), drug-coated balloons (DCB) appear to perform just as well over the long term as thin-strut drug-eluting stents after accounting for differences in patient characteristics, Polish registry data suggest. Patients whose first-time DES ISR was treated with DCB had higher 3 …
FDA Approves Shockwave Intravascular Lithotripsy for Calcified ...
WEBFeb 16, 2021 · (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially …
Watchman FLX Gets DAPT Option Added to Label | tctmd.com
WEBSep 6, 2022 · The addition of DAPT as an option was announced Tuesday by Boston Scientific. DAPT is the recommended antithrombotic approach on the label of another LAA occlusion device, the Amplatzer Amulet (Abbott), with oral anticoagulation recommended only when residual flow around the device is greater than 5 mm. The revised labeling for Watchman FLX ...
Skip to content